Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Current Deferred Revenue (2020 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Current Deferred Revenue for 6 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 20.36% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, down 20.36% year-over-year, with the annual reading at $2.6 million for FY2025, 227.18% up from the prior year.
  • Current Deferred Revenue hit $2.0 million in Q4 2025 for Vistagen Therapeutics, down from $2.1 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $2.8 million in Q1 2022 to a low of $712300.0 in Q3 2022.
  • Historically, Current Deferred Revenue has averaged $1.6 million across 5 years, with a median of $1.4 million in 2021.
  • Biggest five-year swings in Current Deferred Revenue: crashed 74.5% in 2023 and later surged 227.18% in 2025.
  • Year by year, Current Deferred Revenue stood at $1.4 million in 2021, then plummeted by 49.85% to $712300.0 in 2022, then surged by 147.48% to $1.8 million in 2023, then surged by 42.39% to $2.5 million in 2024, then decreased by 20.36% to $2.0 million in 2025.
  • Business Quant data shows Current Deferred Revenue for VTGN at $2.0 million in Q4 2025, $2.1 million in Q3 2025, and $2.5 million in Q2 2025.